BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 18279764)

  • 21. Time to disease recurrence in basal-type breast cancers: effects of tumor size and lymph node status.
    Dent R; Hanna WM; Trudeau M; Rawlinson E; Sun P; Narod SA
    Cancer; 2009 Nov; 115(21):4917-23. PubMed ID: 19691094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer.
    Mansell J; Monypenny IJ; Skene AI; Abram P; Carpenter R; Gattuso JM; Wilson CR; Angerson WJ; Doughty JC
    Breast Cancer Res Treat; 2009 Sep; 117(1):91-8. PubMed ID: 19112615
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
    Wardley AM
    Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.
    Watanabe T; Sano M; Takashima S; Kitaya T; Tokuda Y; Yoshimoto M; Kohno N; Nakagami K; Iwata H; Shimozuma K; Sonoo H; Tsuda H; Sakamoto G; Ohashi Y
    J Clin Oncol; 2009 Mar; 27(9):1368-74. PubMed ID: 19204202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A perioperative screening for metastatic disease is not indicated in patients with primary breast cancer and no clinical signs of tumor spread].
    Gerber B; Seitz E; Müller H; Krause A; Reimer T; Janni W; Kundt G; Friese K
    Zentralbl Gynakol; 2004 Aug; 126(4):275-9. PubMed ID: 15389380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic factors for survival in breast cancer patients who developed distant metastasis subsequent to definitive surgery.
    Kuru B; Camlibel M; Dinc S; Gulcelik MA; Gonullu D; Alagol H
    Singapore Med J; 2008 Nov; 49(11):904-11. PubMed ID: 19037557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recurrence dynamics does not depend on the recurrence site.
    Demicheli R; Biganzoli E; Boracchi P; Greco M; Retsky MW
    Breast Cancer Res; 2008; 10(5):R83. PubMed ID: 18844974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.
    Ejlertsen B; Mouridsen HT; Jensen MB
    Acta Oncol; 2008; 47(4):662-71. PubMed ID: 18465334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact on regional recurrence and survival of axillary surgery in women with node-negative primary breast cancer.
    Axelsson CK; Düring M; Christiansen PM; Wamberg PA; Søe KL; Møller S;
    Br J Surg; 2009 Jan; 96(1):40-6. PubMed ID: 19108002
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Follicular thyroid carcinoma in an iodine-replete endemic goiter region: a prospectively collected, retrospectively analyzed clinical trial.
    Asari R; Koperek O; Scheuba C; Riss P; Kaserer K; Hoffmann M; Niederle B
    Ann Surg; 2009 Jun; 249(6):1023-31. PubMed ID: 19474675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rethinking TNM: a breast cancer classification to guide to treatment and facilitate research.
    Veronesi U; Zurrida S; Viale G; Galimberti V; Arnone P; Nolè F
    Breast J; 2009; 15(3):291-5. PubMed ID: 19645785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.
    Millar EK; Graham PH; O'Toole SA; McNeil CM; Browne L; Morey AL; Eggleton S; Beretov J; Theocharous C; Capp A; Nasser E; Kearsley JH; Delaney G; Papadatos G; Fox C; Sutherland RL
    J Clin Oncol; 2009 Oct; 27(28):4701-8. PubMed ID: 19720911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy.
    Er O; Frye DK; Kau SW; Broglio K; Valero V; Hortobagyi GN; Arun B
    Cancer J; 2008; 14(1):62-8. PubMed ID: 18303485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Surgical resection of the primary tumour is associated with improved survival in patients with distant metastatic breast cancer at diagnosis.
    Ruiterkamp J; Ernst MF; van de Poll-Franse LV; Bosscha K; Tjan-Heijnen VC; Voogd AC
    Eur J Surg Oncol; 2009 Nov; 35(11):1146-51. PubMed ID: 19398188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
    Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low rates of loco-regional recurrence following extended lymph node dissection for gastric cancer.
    Muratore A; Zimmitti G; Lo Tesoriere R; Mellano A; Massucco P; Capussotti L
    Eur J Surg Oncol; 2009 Jun; 35(6):588-92. PubMed ID: 19162429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pelvic lymphadenectomy as an alternative to adjuvant radiotherapy in early stage endometrial cancer at high risk of recurrent lymphatic metastases (stage I)].
    Amato NA; Partipilo V; Mele F; Boscia F; De Marzo P
    Minerva Ginecol; 2009 Feb; 61(1):1-12. PubMed ID: 19204656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
    Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Addressing the future: combination with targeted therapies, adjuvant setting and beyond.
    Goss PE
    Anticancer Drugs; 2008 Mar; 19 Suppl 2():S3-5. PubMed ID: 18337641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.